补中益气汤对老年晚期消化系统恶性肿瘤骨髓抑制及生活质量的影响

doi:10.20047/j.issn1673-7210.2023.05.21

Abstract
Figure/Table
References (31)
Related Citation (15)

Download: PDF (726 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Buzhong Yiqi Decoction on bone marrow suppression and quality of life in elderly patients with advanced digestive system malignant tumors. Methods Eighty-three elderly patients with advanced digestive system malignant tumor admitted to Jiangsu Provincial People’s Hospital from January 2019 to April 2022 were selected and divided into control group (41 cases, XELOX chemotherapy) and observation group (42 cases, XELOX chemotherapy + Buzhong Yiqi Decoction) by random number table method. The clinical efficacy of four weeks after chemotherapy and the myelosuppression of one week after chemotherapy were analyzed and compared between the two groups. The quality of life and immune level before and one week after chemotherapy were analyzed and compared between the two groups. The occurrence of adverse reactions during chemotherapy was recorded. Results At four weeks after chemotherapy, the curative effect of the observation group was better than that of the control group, the difference was statistically significant (P＜0.05). One week after chemotherapy, the incidence of grade Ⅱ and above myelosuppression rate in observation group was lower than that in control group, and the difference was statistically significant (P＜0.05). One week after chemotherapy, the Kanofsky performance status (KPS) score of control group was lower than that of control group before treatment, the KPS score of observation group was higher than that of observation group before treatment, and the levels of immunoglobulin (Ig) M, IgG, and IgA in both groups were higher than those before treatment, KPS score, IgM, IgG, and IgA in the observation group were higher than those in the control group, and the differences were statistically significant (P＜0.05). There were no significant differences in the incidence of nausea, vomiting, diarrhea, and alopecia between the two groups (P＞0.05). Conclusion Buzhong Yiqi Decoction can improve the clinical efficacy of elderly patients with advanced digestive system malignant tumors, reduce the degree of bone marrow suppression, greatly improve the quality of life and immune capacity of patients, and can be widely used in clinical treatment.

Key words： Buzhong Yiqi Decoction Digestive system malignant tumors Bone marrow suppression Quality of life Immune level

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Minghui CAO Jing ZHOU Xi LI Yanfei▲

Cite this article:

ZHU Minghui CAO Jing ZHOU Xi LI Yanfei▲. Effect of Buzhong Yiqi Decoction on bone marrow suppression and quality of life in elderly patients with advanced digestive system malignant tumors[J]. 中国医药导报, 2023, 20(5): 90-93,97.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.05.21 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I5/90

[1] 贾善群，周乾宇，刘慧敏，等.2004—2018年中国消化道恶性肿瘤死亡趋势[J].中华疾病控制杂志，2021，25（9）：46-49.
[2] 刘苏瑶，王琳，许菊青，等.老年消化道肿瘤的营养评估与干预[J].实用老年医学，2020，34（8）：24-28.
[3] 冯芳茗，张伟英，何佳倩，等.消化道癌症患者化疗期间症状群及影响因素分析[J].解放军护理杂志，2020，37（9）：15-18.
[4] 倪玉丹，陈玉红，徐莉，等.老年消化道肿瘤病人化疗相关性味觉改变及对营养、心理状态和生活质量的影响[J].实用老年医学，2021，35（5）：114-117.
[5] 蔡智慧，田肖芳，李蕾，等.聚乙二醇化重组人粒细胞集落刺激因子联合生血宝合剂预防恶性肿瘤化疗后骨髓抑制的临床观察[J].广西医学，2020，42（1）：21-23.
[6] 侯庆梅，杨丽华，修闽宁.155例肿瘤化疗患者中医传统功法锻炼知行现状及影响因素分析[J].护理学报，2020， 27（3）：76-79.
[7] 刘宇，张明泉，马凯，等.国医大师李士懋运用补中益气汤合理阴煎治疗肾之“阴火”探析[J].中华中医药杂志，2020，35（2）：703-705.
[8] 徐细明，周中银，杨继元.消化系统恶性肿瘤的诊断与治疗[M].北京：科学出版社，2009：41-48.
[9] Mehta A，Chai E，Berglund K，et al. Using Admission Karnofsky Performance Status as a Guide for Palliative Care Discharge Needs [J]. J Palliat Med，2021，24（6）：910-913.
[10] Armato SG，Nowak AK. Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma（Version 1.1）[J]. J Thorac Oncol，2018，13（7）：1012-1021.
[11] Hughes R. NCI-CTC vs TNS：which tool is better for grading the severity of chemotherapy-induced peripheral neuropathy？[J]. Nat Clin Pract Neurol，2008，4（2）：68-79.
[12] 滕兆霞，王志英，蔡珂.消化系统肿瘤患者化疗后感染病原学分布及其影响因素分析[J].临床内科杂志，2020， 37（2）：103-107.
[13] 马晶晶，曹梦璐，姚雨君，等.长、短效重组人粒细胞刺激因子对恶性肿瘤患者多周期化疗后白细胞减少症的有效性研究[J].实用医学杂志，2020，36（20）：15-19.
[14] 祝微，王文娟，周杰，等.中医药防治肿瘤放化疗后骨髓抑制的用药规律分析[J].环球中医药，2020，13（1）：18- 21.
[15] 薛梦婷，杨敏，潘娅岚，等.基于AMSTAR 2质量评价和GRADE分级的中医药防治化疗后骨髓抑制疗效系统评价/Meta分析的再评价[J].中国全科医学，2021，24（6）：119-122.
[16] 王睿祺，朱晓锋.扶正养阴方对胃肠道肿瘤术后化疗患者免疫功能及生活质量的影响[J].中国当代医药，2022， 29（26）：25-29.
[17] 肖秋菊，舒诚荣，鲁丽娟，等.艾愈胶囊联合利可君治疗恶性肿瘤化疗后白细胞减少的临床疗效观察[J].中国医药科学，2021，11（10）：79-81.
[18] 赖圆瑾.中医益血汤联合粒细胞集落刺激因子对乳腺癌术后化疗患者血象、免疫功能及预后的影响[J].中国当代医药，2022，29（31）：185-188.
[19] 崔艺馨，米继伟，唐潇然，等.小半夏汤联合穴位针刺治疗乳腺癌术后化疗相关性恶心呕吐的临床研究[J].中国医药，2021，16（8）：1231-1235.
[20] 张晓妮，任秀东，戴玲玲，等.“扶正护膜汤”联合西药治疗Ⅲ期结直肠癌XELOX化疗后骨髓抑制33例临床研究[J].江苏中医药，2020，52（9）：64-68.
[21] 王敏，张梦馨，黄辉，等.培元抗癌汤联合放化疗对非小细胞肺癌患者临床缓解率及血清鳞状上皮细胞癌抗原和癌胚抗原水平的影响[J].中国医药，2022，17（12）：1791- 1794.
[22] 边亚倩，李晶，彭莎，等.基于系统中药学的黄芪补气潜在功效标志物的发掘[J].中国中药杂志，2020，45（14）：3266-3274.
[23] 高泽正，杨映映，李青伟，等.黄芪，人参，炒白术补脾益气经验——仝小林三味小方撷萃[J].吉林中医药，2020， 40（12）：113-117.
[24] 彭磊，覃鸿恩，黄华斌，等.加味人参养荣汤对盆腔复发性宫颈癌同步放化疗期间肿瘤标志物和Th1/Th2细胞因子表达水平的影响[J].河北医学，2022，28（12）：2002- 2007.
[25] 付中学，麻柔.基于数据挖掘麻柔辨治原发免疫性血小板减少症的用药经验[J].世界中西医结合杂志，2021， 16（6）：55-57.
[26] 马金鑫，唐旭东，王凤云，等.唐旭东辨证应用参苓白术散加减治疗功能性腹泻脾胃虚弱证的临床经验[J].辽宁中医杂志，2020，11（5）：53-56.
[27] 孙成磊，杨本官，张贵民，等.加味当归补血颗粒治疗肿瘤相关性贫血的临床观察[J].世界中医药，2020，15（16）：2422-2425.
[28] 巩雅宁，王帅，张静，等.黄芪多糖对老年肺癌患者化疗期间骨髓抑制的改善作用及造血干细胞的影响[J].海南医学院学报，2020，26（19）：126-129.
[29] 李艳川，石紫云，任朵梅，等.黄芪多糖对放射治疗和化学治疗宫颈癌患者免疫功能和不良反应的影响[J].新乡医学院学报，2020，37（6）：135-137.
[30] 孙义长.人参皂苷Rg3联合新辅助放化疗对胃癌患者免疫功能及生存率的影响[J].现代诊断与治疗，2020，11（6）：72-75.
[31] 张千山，李蕾.补中益气汤合益胃汤对晚期胃癌姑息性化疗患者疗效及生活质量的影响[J].四川中医，2021， 10（1）：25-28.